(Galantamine + metformin) is under clinical development by Rejuvenate Biomed and currently in Phase I for Muscle Atrophy. According to GlobalData, Phase I drugs for Muscle Atrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Galantamine + metformin) LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Galantamine + metformin) overview

The combination drug metformin and galantamine (RJx-01) is under development for the treatment of sarcopenia, disuse-induced muscle atrophy and osteoporosis. The drug candidate is a small molecule combination product. It is administered through oral route. It is being developed based on CombinAge and CelegAge, artificial intelligence driven technology platform.

Rejuvenate Biomed overview

Rejuvenate Biomed is a science based healthy aging company developing prescription drugs in healthy aging by repositioning approved drugs. The company is headquartered in Heusden, Oost-Vlaanderen, Belgium.

For a complete picture of (Galantamine + metformin)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.